Statistics

Total Visits

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER252

Select a period of time:

Number of views in the range

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER229

Views

Views
March 202516
April 20252
May 20250
June 20250
July 202511
August 20250
September 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States4
Brazil4
Spain2
Argentina1
Ethiopia1
Saint Kitts And Nevis1
 

Top cities views

Views
Addis Ababa1
Basseterre1
Benalmádena1
Brasília1
Brusque1
Campinas1
Council Bluffs1
Fort Lauderdale1
Los Angeles1
Monte Grande1